Therapeutic area intelligence for Actinic Keratosis with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Companies: 1

Companies

Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. →

Assets

Phase →

Recent signals(1)

ClinicalJuly 10, 2026

Phase 2 Trial of HW211026 for Actinic Keratosis Initiated

A Phase 2 clinical trial has been launched to assess HW211026's efficacy and safety in adult patients with actinic keratosis.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.